SNMMI's communications staff is available to handle your inquiries, arrange interviews with experts, provide copies of research articles and more.
For assistance, please contact Rebecca Maxey, director of communications, at email@example.com or (703) 652-6772.
SNMMI is dedicated to being the premier source of information on nuclear medicine and molecular imaging. SNMMI's online newsroom provides reporters with the information needed to write articles and gain background information on the many topics related to molecular imaging and therapy and nuclear medicine.
SNMMI issues press releases on new research, society updates and industry news for members of the press. Check back frequently to see what's new with SNMMI.
View press releases on the latest research and news from SNMMI.
Please see Tab 6 for information about SNMMI's 2022 Annual Meeting
Nuclear and molecular imaging are vital elements of today's medical practice, adding an additional dimension to diagnosis that can change the way diseases are understood and treated. Nuclear medicine therapies treat specific diseases, such as lymphoma or thyroid cancer, by allowing a high dose of medicine to be delivered directly to a tumor or problem area. SNMMI's fact sheets explain how nuclear medicine and molecular imaging can help diagnose and/or treat a wide range of diseases.
SNMMI publishes two peer-reviewed medical journals—The Journal of Nuclear Medicine (JNM) and The Journal of Nuclear Medicine Technology (JNMT)—which feature the latest in molecular imaging research. JNM and JNMT are the most widely read peer-reviewed publications in molecular imaging, nuclear medicine and allied disciplines.
Every month, JNM brings readers around the globe key research articles on theranostics, nuclear medicine therapy, and imaging of cancer, neurological disease, cardiological disease, and other disease as well as continuing education articles and updates on rapidly changing issues in practice and research. JNM's Newsline offers in-depth reporting on news affecting every facet of the field—the latest scientific events, government decisions, industry developments, socio-economic trends, and a broad selection of reviews from the literature.
Published quarterly, JNMT focuses on technology, quality assurance, radiation safety, and the clinical applications of nuclear medicine. Each issue features continuing education articles written by leading educators in nuclear medicine technology as well as news and updates on practice, licensure, and credentialing for nuclear medicine technologists. Practitioners from across the imaging sciences turn to JNMT for peer-reviewed information related to daily clinical practice.
SNMMI can connect you with subject-matter experts on a variety of topics who are ready to respond to tight deadlines. Contact Rebecca Maxey, director of communications, at firstname.lastname@example.org or at (703) 652-6772, to set up an interview with SNMMI's leadership or with one of its many experts on oncology, brain disease, heart disease, radiopharmaceuticals, reimbursement and more.
Join SNMMI on our social media networks to stay updated on the latest from the society and the nuclear medicine and molecular imaging field.
The SNMMI Annual Meeting is recognized as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. The four-day event, which generally takes place each June, provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field and the clinic.
The SNMMI 2022 Annual Meeting will take place June 11–14, 2022, at the Vancouver Convention Centre in Vancouver, British Columbia, Canada.
Leading molecular imaging and nuclear medicine physicians, radiologists, cardiologists, pharmacists, scientists, lab professionals, and technologists, representing the world's top medical and academic institutions and centers. The 2021 Annual Meeting attracted more than 6,500 registrants.
The 2022 Annual Meeting will take place Saturday, June 11, through Tuesday, June 14, and will feature an exceptional program highlighted by some of the hottest topics in nuclear medicine and molecular imaging, including a science pavilion featuring the latest scientific research, an interactive virtual exhibit hall, categorical seminars, satellite symposia, networking events, and more.
SNMMI offers free registration to accredited members of the press or writers who can supply a letter of assignment from a publication or media outlet. Registration provides access to all open educational sessions, the exhibit area, and press room.
Pre-registration is required. Members of the media should register by contacting Rebecca Maxey at email@example.com or (703) 652-6772.
Follow us on Twitter @SNM_MI for the latest updates from the meeting; our official hashtag is #SNMMI22.
Event details and program information will be available in early 2022 on the SNMMI website.
Research published in the January issue of JNM has confirmed the accuracy of the European Association of Urology risk classification system that groups prostate cancer patients based on their risk of recurrence.
On January 11, CMS announced that it proposes to cover FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under CED in CMS-approved randomized controlled trials. SNMMI reacts.
When assessed together in an AI model, coronary F-18 NaF uptake on PET and quantitative coronary plaque characteristics on CT angiography were found to provide risk prediction superior to that of clinical data alone.
SNMMI and peer medical groups have issued AUC for PSMA PET imaging. Published in the January issue of JNM, the criteria are the product of an international multidisciplinary panel of expert healthcare providers.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.